We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sarepta isn’t allowing an ongoing issue with its lead gene therapy candidate to dampen its enthusiasm for the field. It just announced a tie-up with Lacerta will add another three programs to the eight already on its books and extends its focus beyond mus